American Shared Hosp | 10-Q: FY2025 Q2 Revenue: USD 7.071 M

Revenue: As of FY2025 Q2, the actual value is USD 7.071 M.

EPS: As of FY2025 Q2, the actual value is USD -0.04.

Revenue: The leasing segment generated revenues of $3,571,000 for the three months ended June 30, 2025, and $6,562,000 for the six months ended June 30, 2025, compared to $3,899,000 and $8,152,000 for the same periods in the prior year, respectively.
Depreciation, Amortization, and Other Expense: $960,000 for the three months ended June 30, 2025, and $1,859,000 for the six months ended June 30, 2025, compared to $1,219,000 and $2,311,000 for the same periods in the prior year, respectively.
Interest Expense: $405,000 for the three months ended June 30, 2025, and $803,000 for the six months ended June 30, 2025, compared to $352,000 and $668,000 for the same periods in the prior year, respectively.
Net Income: The leasing segment reported a net income of $96,000 for the three months ended June 30, 2025, and a net loss of $207,000 for the six months ended June 30, 2025, compared to a net loss of $427,000 and $258,000 for the same periods in the prior year, respectively.

Revenue: The direct patient services segment generated revenues of $3,500,000 for the three months ended June 30, 2025, and $6,621,000 for the six months ended June 30, 2025, compared to $3,157,000 and $4,120,000 for the same periods in the prior year, respectively.
Depreciation, Amortization, and Other Expense: $548,000 for the three months ended June 30, 2025, and $1,098,000 for the six months ended June 30, 2025, compared to $304,000 and $546,000 for the same periods in the prior year, respectively.
Interest Expense: $23,000 for the three months ended June 30, 2025, and $58,000 for the six months ended June 30, 2025, compared to $33,000 and $66,000 for the same periods in the prior year, respectively.
Net Income: The direct patient services segment reported a net loss of $376,000 for the three months ended June 30, 2025, and $698,000 for the six months ended June 30, 2025, compared to a net income of $4,029,000 and $3,979,000 for the same periods in the prior year, respectively.

Operating Cash Flow: The company reported net cash provided by operating activities of $2,131,000 for the six months ended June 30, 2025, compared to net cash used in operating activities of - $579,000 for the same period in the prior year.
Free Cash Flow: Not explicitly stated, but the net change in cash, cash equivalents, and restricted cash was $56,000 for the six months ended June 30, 2025.

Core Business Focus: The company plans to continue expanding its direct patient services segment, particularly through the integration of the RI Companies and the new facility in Puebla, Mexico. The company is also focused on maintaining and upgrading its existing equipment, with commitments to purchase and install new Gamma Knife and LINAC systems.
Non-Core Business: The company is not currently pursuing any non-core business activities but is focused on optimizing its existing operations and expanding its core business segments.